Evidence map›Paper›PMID 38709118›Full record

ArticleFuture oncology (London, England)2024

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.

Andrea Sbrana, Sabrina Cappelli, Iacopo Petrini, Laura Bernardini, Valentina Massa, Laura Carrozzi, Antonio Chella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrea SbranaService of Pneumo-Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0003-4460-5282
Sabrina CappelliService of Pneumo-Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Iacopo PetriniMedical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Laura BernardiniMedical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Valentina MassaMedical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Laura CarrozziDepartment of Surgical, Medical & Molecular Pathology & Critical Care Medicine, University of Pisa, Pisa, Italy.
Antonio ChellaService of Pneumo-Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungImidazolesLung NeoplasmsMutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF mutationdrug combinationefficacyNSCLCreal life

Identifiers

PMID38709118
PMCPMC11486151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.